Literature DB >> 28485165

Prognostic significance of the tumor-stroma ratio in gallbladder cancer.

H Li, S L Yuan, Z Z Han, J Huang, L Cui, C Q Jiang, Y Zhang.   

Abstract

In recent years, the tumor-stroma ratio (TSR) has attracted increasing attention as an independent prognostic factor for several solid tumors. However, the importance of the stromal compartment has not been investigated yet in gallbladder cancer (GBC). The objective of this study is to investigate the prognostic value of TSR in GBC and the relationship between TSR and other known prognostic parameters. A total of 51 patients who underwent operations for gallbladder carcinoma were selected for this study. TSR was determined on haematoxylin and eosin (H et E)-stained sections by two independent investigators. Stromal ratio groups were classified as stroma-poor (ratio of stroma 50%). The Mann-Whitney test, the Chi-squared test, the Kaplan-Meier method, and the Cox proportional hazards model were used to analyze the data. The median survival time for patients in the stroma-rich group was 6.00 months (95% CI, 4.47-7.54). In contrast, for the stroma-poor group, the median survival time was 17.00 months (95% CI, 3.64-30.36). The 3-year overall survival rate was 19.7% in the stroma-poor group and 7.2% in the stroma-rich group. Patients with stroma-rich tumors had a worse prognosis than those with stroma-poor tumors (log-rank P = 0.004). According to the univariate analysis, the TSR, differentiation grade, pTNM stage, and operative methods were shown to be related to overall survival (OS) with statistical significance. The hazard ratio (HR) of TSR was 2.428 (95% CI, 1.29-4.58; P = 0.006). However, the TSR did not prove to be an independent prognostic factor in the multivariate analysis. Our study demonstrated that the tumor-stroma ratio (TSR) is an important prognostic parameter for gallbladder cancer (GBC). Stroma-rich tumors were associated with poor overall survival.

Entities:  

Keywords:  gallbladder cancer; tumor microenvironment prognosis.; tumor-stroma ratio

Mesh:

Year:  2017        PMID: 28485165     DOI: 10.4149/neo_2017_413

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  Standardized Assessment of the Tumor-Stroma Ratio in Colorectal Cancer: Interobserver Validation and Reproducibility of a Potential Prognostic Factor.

Authors:  Ricella M Souza da Silva; Eduardo M Queiroga; Alexandre R Paz; Fabiana F P Neves; Karin S Cunha; Eliane P Dias
Journal:  Clin Pathol       Date:  2021-02-11

2.  The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer.

Authors:  Cor J Ravensbergen; Matthew Kuruc; Meaghan Polack; Stijn Crobach; Hein Putter; Hans Gelderblom; Devjit Roy; Rob A E M Tollenaar; Wilma E Mesker
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

3.  Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer.

Authors:  Cor J Ravensbergen; Meaghan Polack; Jessica Roelands; Stijn Crobach; Hein Putter; Hans Gelderblom; Rob A E M Tollenaar; Wilma E Mesker
Journal:  Cells       Date:  2021-10-28       Impact factor: 6.600

4.  The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma.

Authors:  Kenji Kawahara; Shigetsugu Takano; Katsunori Furukawa; Tsukasa Takayashiki; Satoshi Kuboki; Masayuki Ohtsuka
Journal:  Clin Exp Metastasis       Date:  2022-01-09       Impact factor: 5.150

5.  Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations.

Authors:  G W van Pelt; S Kjær-Frifeldt; J H J M van Krieken; R Al Dieri; H Morreau; R A E M Tollenaar; F B Sørensen; W E Mesker
Journal:  Virchows Arch       Date:  2018-07-20       Impact factor: 4.064

6.  The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer.

Authors:  Kiki M H Vangangelt; Andrew R Green; Isabelle M F Heemskerk; Danielle Cohen; Gabi W van Pelt; Marcelo Sobral-Leite; Marjanka K Schmidt; Hein Putter; Emad A Rakha; Rob A E M Tollenaar; Wilma E Mesker
Journal:  Int J Cancer       Date:  2020-01-22       Impact factor: 7.396

7.  Prognostic Significance of the Tumor-Stromal Ratio in Invasive Breast Cancer and a Proposal of a New Ts-TNM Staging System.

Authors:  Qian Xu; Jing-Ping Yuan; Yuan-Yuan Chen; Hong-Yan Zhang; Lin-Wei Wang; Bin Xiong
Journal:  J Oncol       Date:  2020-04-21       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.